<DOC>
	<DOCNO>NCT00530569</DOCNO>
	<brief_summary>About 30 % breast cancer higher normal level cellular marker call HER2 . The amount HER2 often measure breast tissue . A high level marker usually indicate aggressive type breast cancer . Cytokeratin second cellular marker find breast cancer cell . Detection Circulating cytokeratin blood could indicate presence cancer . The Pathology Department Tom Baker Cancer Center study see measuring level circulate HER2 cytokeratin , blood test clinical significance patient breast cancer .</brief_summary>
	<brief_title>Evaluation Clinical Significance Circulating Markers Breast Cancer Patients Undergoing Herceptin Therapy</brief_title>
	<detailed_description>- Single Variate analysis perform correlate variable tumour size , grade , stage , ER status , PR status biopsy HER2 status soluble HER2 level . - Soluble HER2 level analyze continuous categorize variable . - The analysis attempt discern relationship soluble HER2 level , HER2 positive circulate epithelial cell level treatment response . - This provide evidence effect various treatment HER2 level . HER2 level patient treat Herceptin treatment protocol , related clinical disease measure time progression , time failure , duration response duration survival . - An initial model relationship factor soluble HER2 marker establish data .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Albertan woman breast cancer undergo Herceptin therapy part treatment point oneyear period . Greater 80 year age Previous cancer diagnosis ( skin cancer )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Herceptin Therapy</keyword>
</DOC>